Successful treatment of pancreatitis caused by L-asparaginase in clinical practice
Open Access
- 27 January 2024
- journal article
- research article
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (1) , 113-124
Abstract
Treatment intensification of acute lymphoblastic leukemia in children with L-asparaginase (L-ASP) improves therapy effectiveness and shows high survival rates. The unique biological properties of this enzyme make it possible to suppress tumor blasts proliferation by reducing blood asparagine concentration. L-ASP use is limited by toxicity and hypersensitivity reactions observed in 75 % of cases. Although most complications during L-ASP therapy are mild/moderate and are manageable with adequate accompanying therapy, the development of severe side effects leads to forced withdrawal of L-ASP, which significantly reduces the likelihood of a favorable outcome in children with acute lymphoblastic leukemia. One of the most severe toxicity manifestations is the development of asparaginase-associated pancreatitis. It worsens the prognosis and may cause patients’ death. This article presents both current data about asparaginase-associated pancreatitis and treatment experience of this complication at the Research Institute of Pediatric Oncology and Hematology of the N. N. Blokhin National Research Center of Oncology.Keywords
This publication has 11 references indexed in Scilit:
- Options of precision medicine in pediatric oncology: literature reviewRussian Journal of Pediatric Hematology and Oncology, 2022
- Endoscopic transluminal drainage for infected pancreatic necrosisPirogov Russian Journal of Surgery, 2022
- Acute pancreatitis in children with acute lymphoblastic leukemia correlates with L-asparaginase dose intensityPediatric Research, 2021
- The role of asparagine synthetase on nutrient metabolism in pancreatic diseasePancreatology, 2020
- Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 geneDrug Metabolism and Personalized Therapy, 2017
- Asparaginase-associated toxicity in children with acute lymphoblastic leukemiaLeukemia & Lymphoma, 2015
- Acute pancreatitisThe Lancet, 2015
- Successful Use of Octreotide as a Chemoprotectant for Prevention of PEG‐Asparaginase–Induced PancreatitisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- Asparaginase‐associated pancreatitis in childrenBritish Journal of Haematology, 2012
- Octreotide therapy in asparaginase‐associated pancreatitis in childhood acute lymphoblastic leukemiaPediatric Blood & Cancer, 2008